Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 2
2014 9
2015 5
2016 6
2017 3
2018 1
2019 2
2020 2
2021 1
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Harrison CN, et al. Among authors: tantravahi sk. J Clin Oncol. 2022 May 20;40(15):1671-1680. doi: 10.1200/JCO.21.02188. Epub 2022 Feb 18. J Clin Oncol. 2022. PMID: 35180010 Free PMC article. Clinical Trial.
Impact of academic medical center access on outcomes in multiple myeloma.
Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW. Vardell VA, et al. Among authors: tantravahi sk. Am J Hematol. 2023 Jan;98(1):41-48. doi: 10.1002/ajh.26759. Epub 2022 Nov 7. Am J Hematol. 2023. PMID: 36266759 Free article.
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD. Go RS, et al. Among authors: tantravahi sk. J Natl Compr Canc Netw. 2021 Nov;19(11):1277-1303. doi: 10.6004/jnccn.2021.0053. J Natl Compr Canc Netw. 2021. PMID: 34781268
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, Qin QQ, Tantravahi SK, Verstovsek S, Harrison C. Pemmaraju N, et al. Among authors: tantravahi sk. Lancet Haematol. 2022 Jun;9(6):e434-e444. doi: 10.1016/S2352-3026(22)00116-8. Epub 2022 May 13. Lancet Haematol. 2022. PMID: 35576960 Clinical Trial.
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.
Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T. Atanackovic D, et al. Among authors: tantravahi sk. Leukemia. 2020 Jan;34(1):317-321. doi: 10.1038/s41375-019-0536-3. Epub 2019 Aug 13. Leukemia. 2020. PMID: 31409922 Clinical Trial. No abstract available.
Primary non-Hodgkin lymphoma of the ovary.
Yadav BS, George P, Sharma SC, Gorsi U, McClennan E, Martino MA, Chapman J, Chen LM, Prakash G, Malhotra P, Tantravahi SK, Glenn MJ, Werner TL, Baksh K, Sokol L, Morris GJ. Yadav BS, et al. Among authors: tantravahi sk. Semin Oncol. 2014 Jun;41(3):e19-30. doi: 10.1053/j.seminoncol.2014.05.001. Epub 2014 May 16. Semin Oncol. 2014. PMID: 25023360 No abstract available.
31 results